Teladoc Health (NYSE:TDOC) Issues FY 2021 Earnings Guidance

Teladoc Health (NYSE:TDOC) issued an update on its FY 2021 earnings guidance on Monday morning. The company provided EPS guidance of $-3.600-$-3.350 for the period, compared to the Thomson Reuters consensus EPS estimate of $-3.340. The company issued revenue guidance of $2 billion-$2.03 billion, compared to the consensus revenue estimate of $2.01 billion.Teladoc Health also updated its Q3 2021 guidance to $-0.780-$-0.680 EPS.

Shares of NYSE TDOC opened at $136.02 on Thursday. Teladoc Health has a 12 month low of $120.67 and a 12 month high of $308.00. The company has a market cap of $21.66 billion, a price-to-earnings ratio of -23.99 and a beta of 0.24. The company has a quick ratio of 3.79, a current ratio of 4.00 and a debt-to-equity ratio of 0.08. The business has a fifty day simple moving average of $138.60 and a 200-day simple moving average of $152.83.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Tuesday, July 27th. The health services provider reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.27). The business had revenue of $503.14 million during the quarter, compared to analysts’ expectations of $499.85 million. Teladoc Health had a negative return on equity of 1.29% and a negative net margin of 46.86%. The firm’s revenue was up 108.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.34) earnings per share. As a group, sell-side analysts expect that Teladoc Health will post -3.53 EPS for the current fiscal year.

Several research analysts have weighed in on TDOC shares. Deutsche Bank Aktiengesellschaft lowered Teladoc Health from a buy rating to a hold rating and dropped their target price for the stock from $225.00 to $153.00 in a research report on Wednesday, July 28th. Barclays dropped their target price on Teladoc Health from $240.00 to $170.00 and set an equal weight rating on the stock in a research report on Wednesday, July 28th. Oppenheimer lowered their price objective on Teladoc Health from $250.00 to $220.00 and set an outperform rating on the stock in a report on Wednesday, July 28th. Citigroup lowered their price objective on Teladoc Health from $260.00 to $225.00 and set a buy rating on the stock in a report on Wednesday, July 28th. Finally, Argus lowered Teladoc Health from a buy rating to a hold rating in a report on Monday, August 2nd. Twelve equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus price target of $217.75.

In related news, CEO Jason N. Gorevic sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 3rd. The stock was sold at an average price of $150.12, for a total transaction of $1,501,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO David William Sides sold 3,420 shares of Teladoc Health stock in a transaction on Friday, July 30th. The shares were sold at an average price of $154.38, for a total value of $527,979.60. Following the completion of the sale, the chief operating officer now directly owns 14,451 shares of the company’s stock, valued at $2,230,945.38. The disclosure for this sale can be found here. Insiders have sold a total of 17,470 shares of company stock valued at $2,609,504 in the last 90 days. 6.47% of the stock is owned by corporate insiders.

An institutional investor recently raised its position in Teladoc Health stock. Morgan Stanley grew its position in Teladoc Health, Inc. (NYSE:TDOC) by 59.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 2,975,722 shares of the health services provider’s stock after buying an additional 1,109,926 shares during the period. Morgan Stanley owned 1.87% of Teladoc Health worth $494,832,000 at the end of the most recent reporting period. Institutional investors own 79.43% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Featured Article: What factors cause inflation to rise?

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.